» Articles » PMID: 28573668

Establishing a Chemical Genetic Link Between Bruton Tyrosine Kinase Activity in Malignant B Cells and Cell Functions Involved in the Micro-environmental Dialogue

Overview
Journal Br J Haematol
Specialty Hematology
Date 2017 Jun 3
PMID 28573668
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

To elucidate their mechanism of action, inhibitors of Bruton tyrosine kinase (BTK) and resistant BTK mutants were employed to dissect target-dependent cellular functions. BTK-C481S and -T474I, expressed in Ramos and NALM-6 cells, maintained BTK auto-phosphorylation under treatment with ibrutinib or dasatinib, respectively, which showed only modest cytotoxicity. Retained activity of BTK-T474 partially rescued cell migration from inhibition by dasatinib. Importantly, resistant BTK mutants reconstituted B cell receptor-triggered chemokine secretion in the presence of corresponding inhibitors, demonstrating that BTK activity is connected with cell-intrinsic functions of malignant B cells with importance for their dialogue with the micro-environment.

Citing Articles

Functional impact and molecular binding modes of drugs that target the PI3K isoform p110δ.

Hassenruck F, Farina-Morillas M, Neumann L, Landini F, Blakemore S, Rabipour M Commun Biol. 2023; 6(1):603.

PMID: 37277510 PMC: 10241892. DOI: 10.1038/s42003-023-04921-z.


A mechanism for localized dynamics-driven activation in Bruton's tyrosine kinase.

Qiu S, Liu Y, Li Q R Soc Open Sci. 2021; 8(8):210066.

PMID: 34457331 PMC: 8371364. DOI: 10.1098/rsos.210066.


Constitutive activation of Lyn kinase enhances BCR responsiveness, but not the development of CLL in Eµ-TCL1 mice.

Kohlhas V, Hallek M, Nguyen P Blood Adv. 2020; 4(24):6106-6116.

PMID: 33351104 PMC: 7756995. DOI: 10.1182/bloodadvances.2020002584.


Relevant Cytokines in the B Cell Lymphoma Micro-Environment.

Krause G, Hassenruck F, Hallek M Cancers (Basel). 2020; 12(9).

PMID: 32899476 PMC: 7564074. DOI: 10.3390/cancers12092525.


Cell line-based assessment of BTK inhibitors.

Krause G, Hassenruck F, Hallek M Br J Pharmacol. 2020; 177(9):2163-2165.

PMID: 31994176 PMC: 7161538. DOI: 10.1111/bph.14948.